Cargando…

Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO

OBJECTIVES: To describe the clinical course and neuropathology at autopsy of a patient with neuromyelitis optica (NMO) treated with alemtuzumab. METHODS: Case report. RESULTS: A 61-year-old woman with aquaporin-4 immunoglobulin G antibody seropositive NMO had 10 clinical relapses in 4 years despite...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gelfand, Jeffrey M., Cotter, Jennifer, Klingman, Jeffrey, Huang, Eric J., Cree, Bruce A.C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204228/ https://www.ncbi.nlm.nih.gov/pubmed/25340086 http://dx.doi.org/10.1212/NXI.0000000000000034

Ejemplares similares

Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy?
por: Fujihara, Kazuo, et al.
Publicado: (2014)

Finding NMO
por: Daneman, Richard
Publicado: (2016)

Therapy of NMO spectrum disorders
por: Biswas, Atanu, et al.
Publicado: (2015)

Neurodegeneration in MS and NMO: The Eye and the Blood
por: Petzold, Axel, et al.
Publicado: (2011)

Neuromyelitis optica (NMO) and autoimmune thyroiditis
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2015)

Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy
por: Rinaldi, Francesca, et al.
Publicado: (2017)

Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD
por: Zeka, Bleranda, et al.
Publicado: (2016)

Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS
por: Zeka, Bleranda, et al.
Publicado: (2015)

Inclusion Body Myositis Treated with Alemtuzumab
por: Sá, Juliana, et al.
Publicado: (2019)

Autoimmune thyroiditis associated with neuromyelitis optica (NMO)
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2015)

Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease: CHANCE(NMO) Study
por: Hümmert, Martin W., et al.
Publicado: (2022)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study
por: Valentino, Paola, et al.
Publicado: (2016)

Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
por: Borisow, Nadja, et al.
Publicado: (2018)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

CNS resident macrophages enhance dysfunctional angiogenesis and circulating monocytes infiltration in brain arteriovenous malformation
por: Ma, Li, et al.
Publicado: (2023)

Clodronate is not protective in lethal viral encephalitis despite substantially reducing inflammatory monocyte infiltration in the CNS
por: Spiteri, Alanna G., et al.
Publicado: (2023)

Emerging safety issues in alemtuzumab-treated MS patients
por: Killestein, Joep, et al.
Publicado: (2019)

Where Do AQP4 Antibodies Fit in the Pathogenesis of NMO?
por: Kinoshita, Makoto, et al.
Publicado: (2012)

NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
por: Weinshenker, Brian G., et al.
Publicado: (2006)

Wallenda-Nmo Axis Regulates Growth via Hippo Signaling
por: Wang, Xianping, et al.
Publicado: (2021)

Wernicke’s Encephalopathy Precipitated by Area Postrema Syndrome of NMO-SD
por: Anuradha, Mahto, et al.
Publicado: (2023)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021)

Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis
por: Graves, Jennifer, et al.
Publicado: (2013)

Data of safety in a single-center alemtuzumab treated population
por: di Ioia, Maria, et al.
Publicado: (2020)

Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
por: Vaknin-Dembinsky, Adi, et al.
Publicado: (2016)

3D-DIR for early differential diagnostic and prognostic evaluation of NMO
por: Wang, Yanbing, et al.
Publicado: (2016)

Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO
por: Higuchi, Osamu, et al.
Publicado: (2016)

Identification of geraldol as an inhibitor of aquaporin-4 binding by NMO-IgG
por: Wang, Jie, et al.
Publicado: (2020)

COVID-19 infection in NMO/SD patients: a French survey
por: Zeidan, Sinéad, et al.
Publicado: (2020)

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
por: Yeo, Tianrong, et al.
Publicado: (2019)

An Atypical Presentation of Chronic Inflammatory Myelin Degeneration in Neuromyelitis Optica (NMO)
por: Allu, Sai Vishnu Vardhan, et al.
Publicado: (2023)

A Novel approach using O-CVP to treat paraneoplastic NMO spectrum disorder associated with follicular lymphoma
por: Palmer, David Antony, et al.
Publicado: (2022)

ALEMTUZUMAB FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION
por: Girgis, Reda, et al.
Publicado: (2020)

An Autopsy Case of Mesenteric Panniculitis with Massive Pleural Effusions
por: Kobayashi, Hiroshi, et al.
Publicado: (2018)

Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?
por: Mantero, Vittorio, et al.
Publicado: (2020)

EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab
por: van de Langerijt, B., et al.
Publicado: (2010)

Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab
por: Kowarik, Markus C., et al.
Publicado: (2016)

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
por: Cuker, Adam, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5ih6e891nf9d4kupck8n61mh1b